3 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Plexiform Neurofibroma: new trials by email Literature Review of Plexiform Neurofibroma trials Research Report on Plexiform Neurofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 FCN-159 - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 160 | 2021-03-26 | 2024-11-12 |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Mirdametinib (PD-0325901) oral capsule or dispersible tablet - Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) | Phase 2 | Active not recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 114 | 2019-09-29 | 2026-10-06 |
| Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. Trametinib - Low-grade Glioma, Plexiform Neurofibroma | Phase 2 | Active not recruiting | St. Justine's Hospital | 114 | 2018-08-16 | 2026-04-24 |
Neurofibroma, Plexiform (3) · Neurofibromatosis 1 (3) · Brain Neoplasms (1) · Glioma (1) · Neurofibroma (1) · Neurofibromatoses (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Heredodegenerative Disorders, Nervous System (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Nerve Tissue (3) · Neoplastic Syndromes, Hereditary (3) · Nerve Sheath Neoplasms (3) · Nervous System Diseases (3) · Nervous System Neoplasms (3) · Neurocutaneous Syndromes (3) · Neurodegenerative Diseases (3) · Neuromuscular Diseases (3) · Peripheral Nervous System Diseases (3) · Peripheral Nervous System Neoplasms (3)
mirdametinib (1) · trametinib (1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) · St. Justine's Hospital (1)
United States (2) · Canada (1) · China (1) · Spain (1)